JP2016539164A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539164A5 JP2016539164A5 JP2016536659A JP2016536659A JP2016539164A5 JP 2016539164 A5 JP2016539164 A5 JP 2016539164A5 JP 2016536659 A JP2016536659 A JP 2016536659A JP 2016536659 A JP2016536659 A JP 2016536659A JP 2016539164 A5 JP2016539164 A5 JP 2016539164A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutically acceptable
- acceptable salt
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 12
- 239000011780 sodium chloride Substances 0.000 claims 12
- 230000002459 sustained Effects 0.000 claims 11
- DQCKKXVULJGBQN-XFWGSAIBSA-N Naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 8
- 229960003086 Naltrexone Drugs 0.000 claims 8
- SNPPWIUOZRMYNY-UHFFFAOYSA-N Bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 7
- 229960001058 Bupropion Drugs 0.000 claims 7
- 230000000271 cardiovascular Effects 0.000 claims 7
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 6
- 208000010125 Myocardial Infarction Diseases 0.000 claims 3
- 230000002411 adverse Effects 0.000 claims 3
- 230000000250 revascularization Effects 0.000 claims 3
- 206010002388 Angina unstable Diseases 0.000 claims 2
- 206010003119 Arrhythmia Diseases 0.000 claims 2
- 206010003658 Atrial fibrillation Diseases 0.000 claims 2
- 206010007521 Cardiac arrhythmias Diseases 0.000 claims 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010033307 Overweight Diseases 0.000 claims 2
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims 2
- 208000007814 Unstable Angina Diseases 0.000 claims 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 2
- 235000020825 overweight Nutrition 0.000 claims 2
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010002383 Angina pectoris Diseases 0.000 claims 1
- 210000003423 Ankle Anatomy 0.000 claims 1
- 210000001367 Arteries Anatomy 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010058108 Dyslipidaemia Diseases 0.000 claims 1
- 206010014486 Elevated triglyceride Diseases 0.000 claims 1
- 206010061227 Lipid metabolism disease Diseases 0.000 claims 1
- 210000003141 Lower Extremity Anatomy 0.000 claims 1
- 208000004301 Sinus Arrhythmia Diseases 0.000 claims 1
- 208000003663 Ventricular Fibrillation Diseases 0.000 claims 1
- 206010065341 Ventricular tachyarrhythmia Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 201000006233 congestive heart failure Diseases 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 230000000302 ischemic Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002093 peripheral Effects 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Claims (19)
- 対象における主要有害心血管事象(MACE)の危険の低減において使用するための、ナルトレキソン又は薬学的に許容されるその塩及びブプロピオン又は薬学的に許容されるその塩を含む組成物。
- 対象が、MACEの危険が増大しているものである、請求項1に記載の組成物。
- 現在MACEの高い危険がない対象におけるMACEの発症を予防しまたは遅延する、請求項1に記載の組成物。
- 対象が、処置の時点で、次の特徴:II型糖尿病;既存の心血管疾患若しくは心血管疾患の高い可能性;うっ血性心不全;心血管疾患の家族歴;現在の喫煙者;心血管疾患に遺伝的に罹患しやすい;心不整脈を有する若しくは有したことがある;心房細動、心室細動若しくは頻脈性不整脈を有する若しくは有したことがある;洞性不整脈を有さない;不安定アンギナを有する;高血圧を有する;脳卒中を有したことがある若しくは脳卒中の高い危険がある;動脈瘤を有する;又はトリグリセリドの上昇、LDLの上昇及び/又は低HDLを有する、の1つ又は複数を有する、請求項1から3のいずれか一項に記載の組成物。
- 対象が心血管疾患の確定診断又は心血管疾患の高い可能性のいずれかを有し、前記対象が、同定より前の3ヵ月超の確認された心筋梗塞の病歴;冠血行再建の病歴;頸動脈若しくは末梢血行再建の病歴;虚血性変化を伴うアンギナ;段階的運動試験でのECG変化;心臓画像検査陽性;同定より前の2年以内の足関節上腕血圧指数<0.9;又は、処置前の2年以内の冠動脈、頸動脈若しくは下肢動脈の50%超狭窄の少なくとも1つを有する、請求項4に記載の組成物。
- 対象が心房細動の病歴を有する、請求項4に記載の組成物。
- 対象が肥満又は体重過多である、請求項1から6のいずれか一項に記載の組成物。
- 対象が肥満又は体重過多ではない、請求項1から6のいずれか一項に記載の組成物。
- 対象が心血管系状態、糖尿病、高血圧、脂質異常症、血糖状態及び抑うつからなる群から選択される1つ又は複数の状態の管理のための投薬療法を同時に受けている、請求項1から8のいずれか一項に記載の組成物。
- 対象が2型糖尿病を6年未満有していたことがある、請求項1から9のいずれか一項に記載の組成物。
- 対象が現在、2型糖尿病を有さない喫煙者である、請求項1から9のいずれか一項に記載の組成物。
- MACE、四点拡張MACE、五点拡張MACE、心血管（CV）死、非致死性心筋梗塞（MI）、脳卒中、致死性脳卒中、非致死性脳卒中、非致死性HUSA(不安定アンギナのための入院)、冠血行再建手順及び/又は全死因死亡率からなる群から選択される1つ又は複数の事象の最初の発生までの時間を増加させる、請求項1から11のいずれか一項に記載の組成物。
- 前記主要有害心血管事象が心血管死、非致死性心筋梗塞、心不整脈又は非致死性脳卒中である、請求項1から12のいずれか一項に記載の組成物。
- 前記主要有害心血管事象が心血管死である、請求項1から12のいずれか一項に記載の組成物。
- 前記組成物を投与する工程が前記対象の体重の5%、4%、3%、2%又は1%より多くの体重減少をもたらす、請求項1から14のいずれか一項に記載の組成物。
- ナルトレキソン及びブプロピオンの1つ若しくは両方又は薬学的に許容されるそれらの塩が、徐放性製剤で処方される、請求項1から15のいずれか一項に記載の組成物。
- ナルトレキソン及びブプロピオンが徐放性ナルトレキソン32mg及び徐放性ブプロピオン360mg又は薬学的に許容されるそれらの塩の一日量で投与される、請求項1から16のいずれか一項に記載の組成物。
- 前記対象が少なくとも12週間処置される、請求項1から17のいずれか一項に記載の組成物。
- 対象が、
処置の第1週に毎日、前記徐放性ナルトレキソン又は薬学的に許容されるその塩8mg及び前記徐放性ブプロピオン又は薬学的に許容されるその塩90mg;
処置の第2週に毎日、前記徐放性ナルトレキソン又は薬学的に許容されるその塩16mg及び前記徐放性ブプロピオン又は薬学的に許容されるその塩180mg;
処置の第3週に毎日、前記徐放性ナルトレキソン又は薬学的に許容されるその塩24mg及び前記徐放性ブプロピオン又は薬学的に許容されるその塩270mg;並びに
処置の第4週及び処置の任意の続く週に毎日、前記徐放性ナルトレキソン又は薬学的に許容されるその塩32mg及び前記徐放性ブプロピオン又は薬学的に許容されるその塩360mg、
を投与される、請求項1から18のいずれか一項に記載の組成物。
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913216P | 2013-12-06 | 2013-12-06 | |
| US61/913,216 | 2013-12-06 | ||
| US201361914938P | 2013-12-11 | 2013-12-11 | |
| US61/914,938 | 2013-12-11 | ||
| US201461984580P | 2014-04-25 | 2014-04-25 | |
| US61/984,580 | 2014-04-25 | ||
| US14/322,810 US8969371B1 (en) | 2013-12-06 | 2014-07-02 | Compositions and methods for weight loss in at risk patient populations |
| US14/322,810 | 2014-07-02 | ||
| PCT/US2014/068527 WO2015085044A1 (en) | 2013-12-06 | 2014-12-04 | Compositions and methods for reducing major adverse cardiovascular events |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019220444A Division JP7204634B2 (ja) | 2013-12-06 | 2019-12-05 | 主要有害心血管事象を低減するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539164A JP2016539164A (ja) | 2016-12-15 |
| JP2016539164A5 true JP2016539164A5 (ja) | 2018-01-18 |
| JP6665094B2 JP6665094B2 (ja) | 2020-03-13 |
Family
ID=52575014
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536659A Active JP6665094B2 (ja) | 2013-12-06 | 2014-12-04 | 主要有害心血管事象を低減するための組成物及び方法 |
| JP2019220444A Active JP7204634B2 (ja) | 2013-12-06 | 2019-12-05 | 主要有害心血管事象を低減するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019220444A Active JP7204634B2 (ja) | 2013-12-06 | 2019-12-05 | 主要有害心血管事象を低減するための組成物及び方法 |
Country Status (33)
| Country | Link |
|---|---|
| US (8) | US8969371B1 (ja) |
| EP (2) | EP3076971B1 (ja) |
| JP (2) | JP6665094B2 (ja) |
| KR (3) | KR102472432B1 (ja) |
| CN (3) | CN105899210A (ja) |
| AU (1) | AU2014360492A1 (ja) |
| BR (1) | BR112016012755A2 (ja) |
| CA (1) | CA2932127C (ja) |
| CL (1) | CL2016001362A1 (ja) |
| CR (1) | CR20160313A (ja) |
| CY (1) | CY1125114T1 (ja) |
| DK (1) | DK3076971T3 (ja) |
| EA (1) | EA201690964A1 (ja) |
| EC (1) | ECSP16057765A (ja) |
| ES (1) | ES2903391T3 (ja) |
| HR (1) | HRP20220058T1 (ja) |
| HU (1) | HUE057551T2 (ja) |
| IL (3) | IL300870A (ja) |
| JO (1) | JOP20140344B1 (ja) |
| LT (1) | LT3076971T (ja) |
| MX (2) | MX2016007231A (ja) |
| PE (1) | PE20161034A1 (ja) |
| PL (1) | PL3076971T3 (ja) |
| PT (1) | PT3076971T (ja) |
| RS (1) | RS62846B1 (ja) |
| RU (1) | RU2711638C2 (ja) |
| SG (1) | SG10201808055QA (ja) |
| SI (1) | SI3076971T1 (ja) |
| TN (1) | TN2016000231A1 (ja) |
| TW (1) | TWI661826B (ja) |
| UY (1) | UY35864A (ja) |
| WO (1) | WO2015085044A1 (ja) |
| ZA (1) | ZA201603831B (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2316456B1 (en) | 2003-04-29 | 2017-06-14 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss comprising an opioid antagonist and bupropion |
| WO2007067341A2 (en) | 2005-11-22 | 2007-06-14 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| MX343867B (es) | 2006-11-09 | 2016-11-25 | Orexigen Therapeutics Inc | Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso. |
| CA2725930A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| US9248123B2 (en) | 2010-01-11 | 2016-02-02 | Orexigen Therapeutics, Inc. | Methods of providing weight loss therapy in patients with major depression |
| AU2013271622B2 (en) * | 2012-06-06 | 2018-03-01 | Nalpropion Pharmaceuticals Llc | Methods of treating overweight and obesity |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
| WO2018027815A1 (zh) * | 2016-08-11 | 2018-02-15 | 华为技术有限公司 | 基于非授权频谱的无线通信方法、基站和终端设备 |
| WO2023107640A1 (en) * | 2021-12-09 | 2023-06-15 | Incarda Therapeutics, Inc. | Inhaled therapy for cardiac arrhythmia |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217353A (en) | 1978-05-19 | 1980-08-12 | E. I. Du Pont De Nemours And Company | Method for inducing anorexia |
| IL58649A (en) | 1978-11-10 | 1982-04-30 | Beecham Group Ltd | Pharmaceutical dispensing container |
| DE3381877D1 (de) | 1982-03-16 | 1990-10-18 | Univ Rockefeller | Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler stoerungen. |
| GB8613689D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| PH23901A (en) | 1987-05-04 | 1989-12-18 | Lilly Co Eli | Treatment of diabetes using fluoxetine |
| US5403595A (en) | 1991-05-07 | 1995-04-04 | Dynagen, Inc. | Controlled, sustained release delivery system for smoking cessation |
| US5486362A (en) | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
| DE4136215A1 (de) | 1991-11-02 | 1993-05-06 | Ferring Arzneimittel Gmbh, 2300 Kiel, De | Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie |
| US5512593A (en) | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
| DK0782445T3 (da) | 1994-09-19 | 2002-05-06 | Bristol Myers Squibb Pharma Co | Kombination af en opioidantagonist og en selektiv serotoningenoptagelsesinhibitor til behandling af alkoholisme og alkoholafhængighed |
| US5627187A (en) | 1995-04-12 | 1997-05-06 | Katz; Bruce E. | 5-FU for treating actinic kerotoses |
| GB9517062D0 (en) | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
| JPH11505547A (ja) | 1996-03-13 | 1999-05-21 | エール ユニバーシティ | ナルトレキソン及び関連化合物を用いる禁煙処置 |
| EP0795327A1 (en) | 1996-03-13 | 1997-09-17 | Pfizer Inc. | Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin |
| US5716976A (en) | 1996-03-13 | 1998-02-10 | Bernstein; Richard K. | Method of treatment for carbohydrate addiction |
| EP1776955B1 (en) | 1996-05-07 | 2012-08-15 | VeroScience LLC | Medical use and composition for the treatment of lipid and glucose metabolism disorders |
| CA2258893C (en) | 1996-06-28 | 2005-06-14 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant sulfamate derivatives useful in treating obesity |
| US5878750A (en) | 1996-11-14 | 1999-03-09 | Clemens; Anton H. | Method of treating the syndrome of coronary heart disease risk factors in humans |
| EP1019088B1 (en) | 1997-10-03 | 2003-02-12 | Cary Medical Corporation | Composition for the treatment of nicotine addiction containing mecamylamine and bupropion |
| US6262049B1 (en) | 1997-10-28 | 2001-07-17 | Schering Corporation | Method of reducing nicotine and tobacco craving in mammals |
| JP2002501892A (ja) | 1998-01-29 | 2002-01-22 | セプラコア インコーポレーテッド | 光学的に純粋な（−）−ビュープロピオンの薬学的使用 |
| US6048322A (en) | 1998-04-15 | 2000-04-11 | Kushida; Clete | Morphometric measurement tool |
| US6589553B2 (en) | 2001-02-08 | 2003-07-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral dosage form |
| US6210716B1 (en) | 1999-02-26 | 2001-04-03 | Andrx Pharmaceuticals, Inc. | Controlled release bupropion formulation |
| NZ514811A (en) | 1999-04-08 | 2005-01-28 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful in reducing blood glucose levels |
| US6071918A (en) | 1999-07-21 | 2000-06-06 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
| EP1215963A4 (en) | 1999-09-15 | 2005-07-27 | Elan Pharm Inc | METHOD FOR THE TREATMENT OF NEUROPATHIC PAIN USING HETEROARYLMETHANSULFONAMIDES |
| US6403657B1 (en) | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
| AR031682A1 (es) | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
| US20020055512A1 (en) | 2000-01-21 | 2002-05-09 | Cortendo Ab. | Compositions for delivery of a cortisol antagonist |
| GB0001449D0 (en) | 2000-01-21 | 2000-03-08 | Cortendo Ab | Compositions |
| WO2001052851A1 (en) | 2000-01-22 | 2001-07-26 | Albert Shulman | Methods for the treatment of substance abuse |
| JP2003520234A (ja) | 2000-01-22 | 2003-07-02 | アルバート シャルマン | 薬物中毒の治療方法 |
| JP2003522144A (ja) | 2000-02-08 | 2003-07-22 | ユーロ−セルティーク，エス．エイ． | オピオイドアゴニストおよびアンタゴニストを含む制御放出組成物 |
| US6306436B1 (en) | 2000-04-28 | 2001-10-23 | Teva Pharmaceuticals Usa, Inc. | Stabilized, acid-free formulation for sustained release of bupropion hydrochloride |
| US6528520B2 (en) | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| DE60134251D1 (de) | 2000-09-18 | 2008-07-10 | Sanos Bioscience As | Verwendung von glp-2-peptiden |
| AU2002314968B2 (en) | 2001-06-08 | 2006-12-07 | Endo Pharmaceuticals, Inc. | Controlled release dosage forms using acrylic polymer, and process for making the same |
| US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
| US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
| SI1414451T1 (sl) | 2001-08-06 | 2009-10-31 | Euro Celtique Sa | Formulacije opioidnega agonista s sproščanja sposobnim in sekvestriranim antagonistom |
| KR20040060917A (ko) | 2001-08-06 | 2004-07-06 | 유로-셀티크 소시에떼 아노뉨 | 오피오이드 남용을 방지하기 위한 조성물 및 방법 |
| US20030087896A1 (en) | 2001-08-09 | 2003-05-08 | Hillel Glover | Treatment of refractory depression with an opiate antagonist and an antidepressant |
| US20040102440A1 (en) | 2002-07-01 | 2004-05-27 | Wong Erik Ho Fong | Method of promoting smoking cessation |
| US20040029941A1 (en) | 2002-05-06 | 2004-02-12 | Jennings Julianne E. | Zonisamide use in obesity and eating disorders |
| BR0309969A (pt) | 2002-05-17 | 2005-04-26 | Merck Patent Gmbh | Uso de compostos que são eficazes como moduladores de receptores seletivos de opiáceos |
| MXPA04011203A (es) | 2002-05-17 | 2005-07-14 | Univ Duke | Metodo para tratar la obesidad. |
| US20040005368A1 (en) | 2002-07-01 | 2004-01-08 | Morris Mann | Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite |
| US6972291B2 (en) | 2002-07-02 | 2005-12-06 | Bernstein Richard K | Method for reducing food intake |
| US7086532B2 (en) | 2003-07-16 | 2006-08-08 | Allergan, Inc. | Titration/compliance pack with increasing doses |
| JP2006507251A (ja) | 2002-09-13 | 2006-03-02 | エーザイ株式会社 | 振せんの治療方法 |
| WO2004071423A2 (en) | 2003-02-05 | 2004-08-26 | Euro-Celtique S.A. | Methods of administering opioid antagonists and compositions thereof |
| WO2004078113A2 (en) | 2003-03-04 | 2004-09-16 | Pharmacia Corporation | Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents |
| CA2522471A1 (en) | 2003-04-14 | 2004-10-28 | Pain Therapeutics, Inc. | Methods for the treatment of pain comprising opioid antagonists |
| EP2316456B1 (en) | 2003-04-29 | 2017-06-14 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss comprising an opioid antagonist and bupropion |
| BRPI0410271A (pt) | 2003-05-16 | 2006-05-16 | Pfizer Prod Inc | combinações terapêuticas de antipsicóticos atìpicos com moduladores de gaba, anticonvulsivantes ou benzodiazepinas |
| US20070099884A1 (en) | 2003-06-06 | 2007-05-03 | Erondu Ngozi E | Combination therapy for the treatment of diabetes |
| CA2539027C (en) | 2003-09-25 | 2010-02-23 | Euro-Celtique S.A. | Pharmaceutical combinations of hydrocodone and naltrexone |
| US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
| US20070149451A1 (en) | 2003-11-17 | 2007-06-28 | Holmes David G | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent |
| CA2553207A1 (en) | 2004-01-13 | 2005-08-04 | Kishore M. Gadde | Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss |
| US20050245541A1 (en) | 2004-03-19 | 2005-11-03 | Elliot Ehrich | Methods for treating alcoholism |
| JP2007536229A (ja) | 2004-05-03 | 2007-12-13 | デューク・ユニバーシティー | 体重減少に作用するための組成物 |
| US20050250838A1 (en) | 2004-05-04 | 2005-11-10 | Challapalli Prasad V | Formulation for sustained delivery |
| JP2008509142A (ja) | 2004-08-03 | 2008-03-27 | オレキシジェン・セラピューティクス・インコーポレーテッド | 体重減少に影響を及ぼすためのブプロピオンと第２の化合物との組合せ |
| WO2007047351A2 (en) | 2005-10-13 | 2007-04-26 | Orexigen Therapeutics, Inc. | Methods for treating hypertension in overweight and obese individuals |
| US20070099947A1 (en) | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
| WO2007067341A2 (en) | 2005-11-22 | 2007-06-14 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
| WO2007089318A2 (en) | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| AR058239A1 (es) | 2005-11-28 | 2008-01-23 | Orexigen Therapeutics Inc | Metodos para tratar trastornos de ansiedad |
| EP1813276A1 (en) | 2006-01-27 | 2007-08-01 | Euro-Celtique S.A. | Tamper resistant dosage forms |
| JP5478245B2 (ja) | 2006-06-05 | 2014-04-23 | オレキシジェン・セラピューティクス・インコーポレーテッド | ナルトレキソンの徐放型配合物 |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| CA2655835C (en) | 2006-06-19 | 2015-07-21 | Alpharma, Inc. | Abuse-resistant pharmaceutical compositions of opioid agonists |
| CA2693992C (en) | 2006-07-20 | 2017-01-31 | Somaxon Pharmaceuticals, Inc. | Methods of improving the pharmacokinetics of doxepin |
| US8682445B2 (en) | 2006-07-28 | 2014-03-25 | Cyberonics, Inc. | Patient management system for treating depression using an implantable medical device |
| KR101479324B1 (ko) | 2006-11-09 | 2015-01-05 | 오렉시젠 세러퓨틱스 인크. | 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형 |
| MX343867B (es) | 2006-11-09 | 2016-11-25 | Orexigen Therapeutics Inc | Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso. |
| GB2447949B (en) | 2007-03-29 | 2010-03-31 | Renasci Consultancy Ltd | A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission |
| US8318813B2 (en) | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
| CA2725930A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| US9248123B2 (en) * | 2010-01-11 | 2016-02-02 | Orexigen Therapeutics, Inc. | Methods of providing weight loss therapy in patients with major depression |
| AR084093A1 (es) | 2010-12-03 | 2013-04-17 | Orexigen Therapeutics Inc | Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica |
| AU2013271622B2 (en) * | 2012-06-06 | 2018-03-01 | Nalpropion Pharmaceuticals Llc | Methods of treating overweight and obesity |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
-
2014
- 2014-07-02 US US14/322,810 patent/US8969371B1/en active Active
- 2014-12-03 JO JOP/2014/0344A patent/JOP20140344B1/ar active
- 2014-12-04 US US15/101,878 patent/US10231962B2/en active Active
- 2014-12-04 JP JP2016536659A patent/JP6665094B2/ja active Active
- 2014-12-04 EP EP14867191.0A patent/EP3076971B1/en active Active
- 2014-12-04 DK DK14867191.0T patent/DK3076971T3/da active
- 2014-12-04 BR BR112016012755A patent/BR112016012755A2/pt not_active Application Discontinuation
- 2014-12-04 LT LTEPPCT/US2014/068527T patent/LT3076971T/lt unknown
- 2014-12-04 MX MX2016007231A patent/MX2016007231A/es unknown
- 2014-12-04 HR HRP20220058TT patent/HRP20220058T1/hr unknown
- 2014-12-04 KR KR1020167017977A patent/KR102472432B1/ko active IP Right Grant
- 2014-12-04 EA EA201690964A patent/EA201690964A1/ru unknown
- 2014-12-04 CA CA2932127A patent/CA2932127C/en active Active
- 2014-12-04 RS RS20220039A patent/RS62846B1/sr unknown
- 2014-12-04 RU RU2016122483A patent/RU2711638C2/ru active
- 2014-12-04 IL IL300870A patent/IL300870A/en unknown
- 2014-12-04 EP EP21202875.7A patent/EP4005571A1/en active Pending
- 2014-12-04 UY UY0001035864A patent/UY35864A/es not_active Application Discontinuation
- 2014-12-04 WO PCT/US2014/068527 patent/WO2015085044A1/en active Application Filing
- 2014-12-04 PE PE2016000724A patent/PE20161034A1/es unknown
- 2014-12-04 PT PT148671910T patent/PT3076971T/pt unknown
- 2014-12-04 AU AU2014360492A patent/AU2014360492A1/en not_active Abandoned
- 2014-12-04 SI SI201431935T patent/SI3076971T1/sl unknown
- 2014-12-04 KR KR1020237036479A patent/KR20230152800A/ko not_active Application Discontinuation
- 2014-12-04 KR KR1020227041333A patent/KR20220165791A/ko not_active Application Discontinuation
- 2014-12-04 CN CN201480072729.8A patent/CN105899210A/zh active Pending
- 2014-12-04 CN CN202111066895.5A patent/CN114404419A/zh active Pending
- 2014-12-04 CR CR20160313A patent/CR20160313A/es unknown
- 2014-12-04 CN CN202310405573.1A patent/CN117159547A/zh active Pending
- 2014-12-04 SG SG10201808055QA patent/SG10201808055QA/en unknown
- 2014-12-04 TN TN2016000231A patent/TN2016000231A1/en unknown
- 2014-12-04 ES ES14867191T patent/ES2903391T3/es active Active
- 2014-12-04 HU HUE14867191A patent/HUE057551T2/hu unknown
- 2014-12-04 PL PL14867191T patent/PL3076971T3/pl unknown
- 2014-12-05 TW TW103142498A patent/TWI661826B/zh active
-
2015
- 2015-03-02 US US14/635,518 patent/US9119850B2/en active Active
- 2015-08-28 US US14/839,792 patent/US9801875B2/en active Active
-
2016
- 2016-05-30 IL IL245919A patent/IL245919A0/en unknown
- 2016-06-02 MX MX2022001251A patent/MX2022001251A/es unknown
- 2016-06-03 CL CL2016001362A patent/CL2016001362A1/es unknown
- 2016-06-06 ZA ZA2016/03831A patent/ZA201603831B/en unknown
- 2016-07-04 EC ECIEPI201657765A patent/ECSP16057765A/es unknown
-
2017
- 2017-10-05 US US15/725,830 patent/US10231964B2/en active Active
-
2019
- 2019-03-18 US US16/356,663 patent/US10835527B2/en active Active
- 2019-03-18 US US16/356,657 patent/US10828294B2/en active Active
- 2019-12-05 JP JP2019220444A patent/JP7204634B2/ja active Active
-
2020
- 2020-11-16 US US17/099,316 patent/US11998542B2/en active Active
-
2021
- 2021-04-07 IL IL282117A patent/IL282117A/en unknown
-
2022
- 2022-01-19 CY CY20221100048T patent/CY1125114T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539164A5 (ja) | ||
| HRP20220058T1 (hr) | Sastavi i metode za smanjenje velikih neželjenih kardiovaskularnih događaja | |
| JP2022062151A5 (ja) | ||
| Stiell et al. | A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm | |
| Tabbalat et al. | Effect of ColchiciNe on the InciDence of atrial fibrillation in open heart surgery patients: END-AF trial | |
| JCS Joint Working Group | Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2008)–Digest Version– | |
| Conde et al. | Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation | |
| WO2009150535A1 (en) | Dronedarone for the prevention of permanent atrial fibrillation | |
| JP2019206562A5 (ja) | ||
| Camm et al. | Medical treatment of atrial fibrillation | |
| JP2015518897A5 (ja) | ||
| Iguchi et al. | Beneficial effects of cilostazol in a patient with recurrent ventricular fibrillation associated with early repolarization syndrome | |
| Onk et al. | Is the preoperative administration of amiodarone or metoprolol more effective in reducing atrial fibrillation: after coronary bypass surgery? | |
| Quah et al. | The management of the older adult patient with anomalous left coronary artery from the pulmonary artery syndrome: a presentation of two cases and review of the literature | |
| Codolosa et al. | Update on ranolazine in the management of angina | |
| Bangalore et al. | Verapamil-sustained release–based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: An INternational VErapamil SR-Trandolapril (INVEST) substudy | |
| Duggan et al. | Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation | |
| JP2020523408A5 (ja) | ||
| Dan Kiselnik et al. | Acute myocarditis and myopathy as presenting manifestations of human immunodeficiency virus infection | |
| Selvaraj et al. | Effect of single intraoperative dose of amiodarone in patients with rheumatic valvular heart disease and atrial fibrillation undergoing valve replacement surgery | |
| Cohen et al. | The management of patients with atrial fibrillation and dronedarone’s place in therapy | |
| Yavuz et al. | Role of endogenous adenosine in atrial fibrillation after coronary artery bypass graft | |
| Nagra et al. | Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale | |
| Andò et al. | Ticagrelor or prasugrel for prevention of stent thrombosis? | |
| Hashmi et al. | Dextrocardia with situs inversus totalis: coronary artery bypass grafting |